October 15, 2009 Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch March 26, 2009 NICHD/NIH TO CONDUCT CLINICAL STUDY WITH AGILE’S WEEKLY, PROGESTIN-ONLY, CONTRACEPTIVE PATCH Agile Therapeutics and NICHD Collaboration Intended to Provide Breast Feeding Mothers with Needed Contraceptive Option
December 9, 2008 AGILE THERAPEUTICS ABSTRACTS ON LEAD PRODUCT, AG200-15 ACCEPTED BY ACOG Phase 2 Results for Low-dose, Weekly Contraceptive Patch to be Presented at ACOG Meeting in May 2009
November 18, 2008 AGILE‘S LEAD PRODUCT, AG200-15, MOVING INTO PIVOTAL PHASE 3 TRIALS Successful Meeting with FDA Provides Clear Development Path for Innovative Birth Control Method: a Low-Dose, Once-Weekly Contraceptive Patch
October 28, 2008 AGILE THERAPEUTICS ANNOUNCES ISSUANCE OF KEY PATENTS FOR ITS SKINFUSIONTM TECHNOLOGY IN CONTRACEPTION Agile’s Phase 3 Product Could Become a Preferred Alternative to Daily Oral Contraceptives
September 3, 2008 AGILE THERAPEUTICS ACHIEVES PHASE 2 STUDY ENDPOINTS IN KEY CLINICAL TRIALS WITH NEW, INNOVATIVE LOW-DOSE CONTRACEPTIVE PATCH Company to Discuss Phase 3 Plans with FDA
August 12, 2008 AGILE THERAPEUTICS APPOINTS INDUSTRY EXPERT AL ALTOMARI, AS CHAIRMAN OF ITS BOARD OF DIRECTORS Brings Over 25 Years of Women’s Health Commercialization Experience. Company to Capitalize on Major Unmet Contraceptive Need
July 23, 2008 AGILE THERAPEUTIC'S SCIENTIFIC ADVISOR SHELDON SEGAL AWARDED PRIX GALIEN USA Pro Bono Humanum Award Recognizes Organization and Segal for Role in Developing Implantable Hormone Delivery Systems
July 8, 2008 AGILE THERAPEUTICS APPOINTS SENIOR EXECUTIVE JEFFREY FRICK AS CHIEF BUSINESS OFFICER Agile Gears Up for Phase 3 Clinical Trials
February 5, 2008 AGILE THERAPEUTICS TO PRESENT AT THE 10TH ANNUAL BIO CEO & INVESTOR CONFERENCE
